QURENasdaqPharmaceutical PreparationsFiscal year ends December 31
uniQure N.V.
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Jul 29, 2026
$22.20+0.42 (+1.93%)
Close on Oct 19, 2026
- Market cap
- $1.47B
- P/E (TTM)
- –
- Dividend yield
- –
uniQure N.V. revenue by segment
By business segment
By product or service
| Revenue | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 | FY2017 | FY2016 | % of revenue | YoY |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| License revenues | $15.93M | $10.13M | $2.76M | $100.00M | $517.40M | $4.35M | – | – | $8.00K | $975.00K | 99.0% | +57.2% |
| Collaboration revenues | $164.00K | $10.87M | $2.25M | $4.77M | $6.60M | $59.00K | – | – | $4.64M | $7.16M | 1.0% | -98.5% |
| Contract manufacturing revenues | $0 | $6.11M | $10.84M | $1.72M | $0 | – | – | – | – | – | 0.0% | -100.0% |
| Collaboration revenues from related parties | – | – | – | – | – | $136.00K | $2.29M | $3.76M | $4.34M | $13.02M | – | – |
| License revenues from related parties | – | – | – | $0 | $0 | $32.97M | $4.99M | $7.50M | $4.12M | $3.94M | – | – |
| Collaborative Revenue Including Revenue From Related Party | – | – | – | $1.80M | $4.20M | $200.00K | $2.30M | $3.80M | – | – | – | – |
By region
From the segment and revenue-disaggregation notes of uniQure's 10-K and 10-Q filings (XBRL). Fourth-quarter figures are the fiscal year less the first nine months. Segment names follow the company's own labels and can change when it reorganizes.